Advertisement

Möglichkeiten einer Immuno- und Zytokintherapie beim metastasierenden Melanom

  • M. Roux
  • G. Mahrle
Conference paper
Part of the Fortschritte der operativen und onkologischen Dermatologie book series (OP.DERMATOLOGIE, volume 9)

Zusammenfassung

Es werden neue Antitumorstrategien dargestellt, welche sich z. T. schon in der klinischen Testung befinden. Hierzu gehören: 1. Die aktive Immunisierung mit Tumorlysaten oder mit virusinfizierten Tumorzellen; 2. Die Therapie mit murinen monoklonalen Antikörpern (MAk), die gegen tumorassoziierte Moleküle gerichtet sind; 3. Behandlung mit Zytokinen wie Inter-leukin-2 (I1-2), Tumornekrosefaktor alpha (TNF-α), die entweder direkt oder über zytotoxi-sche T-Zellen auf den Tumor einwirken; 4. Behandlung mit extrakorporal lymphokinaktivier-ten Killerzellen (LAK) oder mit expandierten tumorinfiltrierenden Lymphozyten (TIL); 5. Behandlung mit molekularbiologisch veränderten, transfizierten Zellen.

Zum einen handelt es sich um eine Immunisierung mit Melanomzellen, die mit dem I1-2 Gen transfiziert wurden, zum anderen um eine Reinfusion von mit dem TNF-α Gen transfizierten TIL. Im ersteren Fall erwartet man durch die vermehrte I1-2 Produktion eine gesteigerte Aktivität von gegen den Tumor gerichteten Killerzellen, im zweiten Fall eine gezieltte TNF-α-Freisetzung am Tumor.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. 1.
    Arienti F, Belli F, Rivoltini L et al. (1993) Adoptive immunotherapy of advanced melanoma patients with interleukin-2 (I1-2)) and tumor-infiltrating lymphocytes selected in vitro with low doses of I1-2. Cancer Immunol Immunother 36:315–322.PubMedCrossRefGoogle Scholar
  2. 2.
    Baars JW, Fonk JC, Scheper RJ et al. (1992) Treatment with tumour infiltrating lymphocytes and interleukin-2 in patients with metastatic melanoma: a pilot study. Biotherapy 4:289–297.PubMedCrossRefGoogle Scholar
  3. 3.
    Bajorin DF, Chapman PB, Wong GY et al. (1992) Treatment with high dose mouse monoclonal (anti-GD3) antibody R24 in patients with metastatic melanoma. Melanoma Res 2: 355–362.PubMedCrossRefGoogle Scholar
  4. 4.
    Falkson CI, Falkson G, Falkson HC (1991) Improved results with the addition of interferon alfa-2b to dacarbazine in the treatment of patients with metastatic malignant melanoma. J Clin Oncol 9:1403–1408.PubMedGoogle Scholar
  5. 5.
    Gansbacher B, Bannerji R, Daniels B et al. (1990) Retroviral vector-mediated gamma-in-terferon gene transfer into tumor cells generates potent and long lasting antitumor immunity. Cancer Res 50:7820–7825.PubMedGoogle Scholar
  6. 6.
    Gansbacher B, Rosenthal FM, Zier K (1993) Retroviral vector-mediated cytokine-gene transfer into tumor cells. Cancer Invest 11:345–354.PubMedCrossRefGoogle Scholar
  7. 7.
    Gansbacher B, Zier K, Cronin K et al. (1992) Retroviral gene transfer induced constitutive expression of I1-2 or interferon-gamma in irradiated human melanoma cells. Blood 80: 2817–2825.PubMedGoogle Scholar
  8. 8.
    Gastl G, Finstad CL, Guarini A et al. (1992) Retroviral vector-mediated lymphokine gene transfer into human renal cancer cells. Cancer Res 52:6229–6236.PubMedGoogle Scholar
  9. 9.
    Hellstrom KE, Hellstrom I, Linsley P, Chen L (1993) On the role of costimulation in tumor immunity. Ann NY Acad Sci 690:225–230.PubMedCrossRefGoogle Scholar
  10. 10.
    Hersey P, McLeod GR, Thomson DB (1991) Treatment of advanced malignant melanoma with recombinant interferon alfa-2a in combination with DTIC: long-term follow-up of two phase II studies. Br J Haematol 1:60–66.CrossRefGoogle Scholar
  11. 11.
    Kasid A, Morecki S, Aebersold P et al. (1990) Human gene transfer: characterization of human tumor-infiltrating lymphocytes as vehicles for retroviral-mediated gene transfer in man. Proc Natl Acad Sci USA 87:473–477.PubMedCrossRefGoogle Scholar
  12. 12.
    Keilholz U, Scheibenbogen C, Tilgen W et al. (1993) Interferon-alpha and I1-2 in the treatment of metastatic melanoma. Comparison of two phase II trials. Cancer 72:607–614.PubMedCrossRefGoogle Scholar
  13. 13.
    Keilholz U, Schlag P, Tilgen W et al. (1992) Regional administration of lymphokine-ac-tivated killer cells can be superior to intravenous application. Cancer 69:2172–2175.PubMedCrossRefGoogle Scholar
  14. 14.
    Kradin RL, Kurnick JT, Lazarus DS et al. (1989) Tumour-infiltrating lymphocytes and interleukin-2 in treatment of advanced cancer. Lancet 1:577–580.PubMedCrossRefGoogle Scholar
  15. 15.
    Lejeune FJ, Lienard D, Leyvraz S, Mirimanoff RO (1993) Regional therapy of melanoma. Eur J Cancer 29 A: 606–612.CrossRefGoogle Scholar
  16. 16.
    Mulder NH, Willemse PH, Schraffordt KH et al. (1990) Dacarbazine (DTIC) and human recombinant interferon alpha 2a (Roferon) in the treatment of disseminated malignant melanoma. Br J Cancer 62:1006–1007.PubMedCrossRefGoogle Scholar
  17. 17.
    Nistico P, Mortarini R, De ML et al. (1992) Cell retargeting by bispecific monoclonal antibodies. Evidence of bypass of intratumor susceptibility to cell lysis in human melanoma. J Clin Invest 90:1093–1099.PubMedCrossRefGoogle Scholar
  18. 18.
    Osanto S, Brouwenstyn N, Vaessen N et al. (1993) Immunization with interleukin-2 trans-fected melanoma cells. A phase I-II study in patients with metastatic melanoma. Hum Gene Ther 4:323–330.PubMedCrossRefGoogle Scholar
  19. 19.
    Porgador A, Gansbacher B, Bannerji R et al. (1993) Anti-metastatic vaccination of tumor-bearing mice with Il-2-gene-inserted tumor cells. Int J Cancer 53:471–477.PubMedCrossRefGoogle Scholar
  20. 20.
    Reisfeld RA (1992) Potential of genetically engineered monoclonal antibodies for cancer immunotherapy. Pigment Cell Res 2:109–112.PubMedGoogle Scholar
  21. 21.
    Ron IG, Inbar MJ, Gutman M et al. (1993) Recombinant interferon alpha-2a in combination with dacarbazine in the treatment of metastatic malignant melanoma: analysis of long-term responding patients. Cancer Immunol Immunother 37:61–66.PubMedCrossRefGoogle Scholar
  22. 22.
    Rosenberg SA, Aebersold P, Cornetta K et al. (1990) Gene transfer into humans-immuno-therapy of patients with advanced melanoma, using tumor-infiltrating lymphocytes modified by retroviral gene transduction [see comments]. N Engl J Med 323:570–578.PubMedCrossRefGoogle Scholar
  23. 23.
    Rosenberg SA, Lotze MT, Yang JC et al. (1993) Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer. J Natl Cancer Inst 85:622–632.PubMedCrossRefGoogle Scholar
  24. 24.
    Saleh MN, Khazaeli MB, Wheeler RH et al. (1992) Phase I trial of the chimeric anti-GD2 monoclonal antibody chl4.18 in patients with malignant melanoma. Hum Antibodies Hybridomas 3:19–24.PubMedGoogle Scholar
  25. 25.
    Saleh MN, Khazaeli MB, Wheeler RH et al. (1992) Phase I trial of the murine monoclonal anti-GD2 antibody 14G2a in metastatic melanoma. Cancer Res 52:4342–4347.PubMedGoogle Scholar
  26. 26.
    Schendel DJ, Gansbacher B (19993) Tumor-specific lysis of human renal cell carcinomas by tumor-infiltrating lymphocytes: modulation of recognition through retroviral transduction of tumor cells with I1-2 complementary DNA and exogenous alpha interferon treatment. Cancer Res 53:4020–4025.Google Scholar
  27. 27.
    Schirrmacher V (1989) Immunobiology and immunotherapy of cancer metastases — ten-year studies in an animal model resulting in the design of an immunotherapy procedure now under clinical testing. Interdisciplinary Science Reviews 14:291–303.Google Scholar
  28. 28.
    Schlag P, Manasterski M, Gerneth T et al. (1992) Active specific immunotherapy with Newcastle-disease-virus-modified autologous tumor cells following resection of liver metastases in colorectal cancer. First evaluation of clinical response of a phase II-trial. Cancer Immunol Immunother 35:325–330.PubMedCrossRefGoogle Scholar
  29. 29.
    Schwürzer-Voit M, Proebstle TM, Staib G et al. (1993) Active specific immunisation (ASI) and antisuppressive therapy combined with monochemotherapy for metastatic melanoma. Arch Dermatol Res 286:219.Google Scholar
  30. 30.
    Sznol M, Clark JW, Smith J2 et al. (1992) Pilot study of I1-2 and lymphokine-activated killer cells combined with immunomodulatory doses of chemotherapy and sequenced with interferon alfa-2a in patients with metastatic melanoma and renal cell carcinoma. J Natl Cancer Inst 84:929–937.PubMedCrossRefGoogle Scholar
  31. 31.
    Tilgen W, Matzku S (1990) Pitfalls in the clinical application of monoclonal antibodies in malignant melanoma: modulation by and impaired accessibility of antigens to monoclonal antibodies. Cancer Treat Rev 17:357–371.PubMedCrossRefGoogle Scholar
  32. 32.
    Veelken H, Rosenthal FM, Schneller F et al. (1992) Combination of I1-2 and interferon-al-pha in renal cell carcinoma and malignant melanoma: a phase II clinical trial. Biotechnol Ther 3:1–4.PubMedGoogle Scholar
  33. 33.
    Vile RG, Hart IR (1993) In vitro and in vivo targeting of gene expression to melanoma cells. Cancer Res 53:962–967.PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1995

Authors and Affiliations

  • M. Roux
  • G. Mahrle

There are no affiliations available

Personalised recommendations